_:nb98e821df7174a1a928ffa762c2136ccxb0
<http://schema.org/description>
"Most patients with myelofibrosis, a rare chronic disorder of the haematopoietic cells of the bone marrow, benefit from drugs from the JAK2 inhibitor class: symptoms are relieved, survival extended and general quality-of-life enhanced. However, two or three years after the start of treatment, some patients develop an aggressive B-cell lymphoma. In a close collaboration between researchers from MedUni Vienna and Vetmeduni Vienna, it has now been shown for the first time that JAK2 inhibitors awaken &quot;dormant&quot; lymphomas in the bone marrow and hence cancer."
<https://medicalxpress.com/news/2018-06-standard-myelofibrosis-drug-awaken-dormant.html>